Julij 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics in GenScript ProBio sta v procesu podpisovanja pogodbe za razvoj in proizvodnjo plazmidov in virusnih vektorjev za prvo linijo ACT Therapeutics's Advanced CAR-T Platform (ACT platform), ki bo prav tako naročena za proizvodnjo surovin za nadaljnje načrte ACT Therapeutics. Pogodba bo zajemala proizvodnjo plazmidov in virusnih vektorjev za prvo linijo platforme ACT Therapeutics Advanced CAR-T.
Kot rezultat tega sporazuma je bil GenScript ProBio povišan v status globalnega partnerja, ki lahko podpira platforme ACT za terapevtiko ACT.
Platforma ACT je tehnologija celične in genske terapije naslednje generacije, ki cilja na antigene raka z vstavljanjem genov, namenjenih ciljanju na te antigene, v imunske celice. Ti geni so dostavljeni v imunske celice z uporabo virusnih vektorjev. GenScript ProBio ima visokokakovosten razvoj virusnega vektorskega procesa in storitveno platformo na enem mestu za proizvodnjo GMP, kar je oboje potrebno za razvoj celične in genske terapije.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing krvni rak. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, izvršni direktor podjetja ACT Therapeutics, je dejal: »Dokončali smo priprave za globalni razvoj platforme ACT prek strateškega partnerstva z GenScript ProBio. Pospešili bomo razvoj zdravljenj, namenjenih neodzivnim in nezdravljivim solidnim rakom.«
O GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
V smeri poslanstva »Inovacija skozi sodelovanje« je GenScript ProBio zavezan pomagati strankam skrajšati časovni okvir za razvoj bioloških zdravil od odkritja do komercializacije, znatno znižati stroške raziskav in razvoja ter zgraditi bolj zdravo prihodnost.
